PTPN13 and chronic myelogenous leukemia, BCR-ABL1 positive: In a murine model of CML, we determine treatment with Imatinib (IM; a TKI inhibitor) plus a Fap1-blocking peptide prevented chronic phase (CP) relapse or blast crisis (BC) progression, although IM alone did not [12].